BRPI0519355A2 - compostos para tratamento contra flaviviridae - Google Patents

compostos para tratamento contra flaviviridae

Info

Publication number
BRPI0519355A2
BRPI0519355A2 BRPI0519355-9A BRPI0519355A BRPI0519355A2 BR PI0519355 A2 BRPI0519355 A2 BR PI0519355A2 BR PI0519355 A BRPI0519355 A BR PI0519355A BR PI0519355 A2 BRPI0519355 A2 BR PI0519355A2
Authority
BR
Brazil
Prior art keywords
flaviviridae
compounds
treatment against
against flaviviridae
preventing
Prior art date
Application number
BRPI0519355-9A
Other languages
English (en)
Inventor
Beat Weidmann
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0519355A2 publication Critical patent/BRPI0519355A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

COMPOSTOS PARA TRATAMENTO CONTRA FLAVIVIRIDAE. São reveladas ciclosporinas de ligação de ciclofilina não imu- nossupressivas, por exemplo, de fórmula I, Ia ou II conforme definido aqui, neste requerimento de patente, tendo propriedades úteis na prevenção ou tratamento de infecções por Flaviviridae e doenças induzidas por Flaviviridae.
BRPI0519355-9A 2004-12-23 2005-12-20 compostos para tratamento contra flaviviridae BRPI0519355A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63867604P 2004-12-23 2004-12-23
PCT/US2005/046058 WO2006071618A1 (en) 2004-12-23 2005-12-20 Compounds for flaviviridae treatment

Publications (1)

Publication Number Publication Date
BRPI0519355A2 true BRPI0519355A2 (pt) 2009-01-20

Family

ID=36218613

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0519355-9A BRPI0519355A2 (pt) 2004-12-23 2005-12-20 compostos para tratamento contra flaviviridae

Country Status (17)

Country Link
US (1) US20090214464A1 (pt)
EP (1) EP1830870A1 (pt)
JP (1) JP2008525458A (pt)
KR (1) KR20070089954A (pt)
CN (1) CN101084005A (pt)
AU (1) AU2005322241B2 (pt)
BR (1) BRPI0519355A2 (pt)
CA (1) CA2587586A1 (pt)
IL (1) IL183780A0 (pt)
MA (1) MA29097B1 (pt)
MX (1) MX2007007721A (pt)
NO (1) NO20073765L (pt)
NZ (1) NZ555142A (pt)
RU (1) RU2007128098A (pt)
TN (1) TNSN07240A1 (pt)
WO (1) WO2006071618A1 (pt)
ZA (1) ZA200703907B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006524232A (ja) 2003-03-17 2006-10-26 アルバニー モレキュラー リサーチ インコーポレーティッド 新規サイクロスポリン
JP2008514701A (ja) 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド シクロスポリンアルキン類似体およびそれらの薬学的使用
EP1804823A4 (en) 2004-09-29 2010-06-09 Amr Technology Inc NEW CYCLOSPORIN ANALOGUE AND ITS PHARMACEUTICAL APPLICATIONS
US7196161B2 (en) 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
US7361636B2 (en) 2004-10-06 2008-04-22 Amr Technology, Inc. Cyclosporin alkynes and their utility as pharmaceutical agents
US8329658B2 (en) 2005-09-30 2012-12-11 Scynexis, Inc. Arylalkyl and heteroarylalkyl derivatives of cyclosporine A for the treatment and prevention of viral infection
BRPI0616476A2 (pt) 2005-09-30 2011-06-21 Scynexis Inc uso de uma quantidade terapeuticamente eficaz de um derivado de ciclosporina, e, composição farmacêutica
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
ATE502633T1 (de) 2006-05-19 2011-04-15 Scynexis Inc Cyclosporins zur behandlung und vorbeugung von augenerkrankungen
US7576057B2 (en) 2006-11-20 2009-08-18 Scynexis, Inc. Cyclic peptides
US9090671B2 (en) 2008-06-06 2015-07-28 Scynexis, Inc. Macrocyclic peptides
EP2376524B1 (en) 2008-12-31 2017-03-15 Cypralis Limited Derivatives of cyclosporin a
US20110117055A1 (en) 2009-11-19 2011-05-19 Macdonald James E Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE148469T1 (de) * 1990-11-02 1997-02-15 Sandoz Ag Zyklosporine
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
FR2757521B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757522B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
GB9811854D0 (en) * 1998-06-02 1998-07-29 Ciba Geigy Ag Organic compounds
AR031010A1 (es) * 2000-10-19 2003-09-03 Fujisawa Pharmaceutical Co Una composicion farmaceutica, util para inhibir el dano celular
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds
UA88484C2 (ru) * 2004-10-01 2009-10-26 Дебиофарм Са ПРИМЕНЕНИЕ [D-MeAla]3-[EtVal]4-ЦИКЛОСПОРИНА ДЛЯ ЛЕЧЕНИЯ ИНФЕКЦИИ ГЕПАТИТА С И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ ВКЛЮЧАЕТ [D-MeAla]3-[EtVal]4-ЦИКЛОСПОРИН
CA2587793A1 (en) * 2004-12-23 2006-07-06 Novartis Ag Compositions for hcv treatment

Also Published As

Publication number Publication date
AU2005322241A1 (en) 2006-07-06
KR20070089954A (ko) 2007-09-04
CA2587586A1 (en) 2006-07-06
ZA200703907B (en) 2009-08-26
EP1830870A1 (en) 2007-09-12
JP2008525458A (ja) 2008-07-17
IL183780A0 (en) 2007-09-20
WO2006071618A1 (en) 2006-07-06
RU2007128098A (ru) 2009-01-27
NO20073765L (no) 2007-09-19
MX2007007721A (es) 2007-08-14
CN101084005A (zh) 2007-12-05
NZ555142A (en) 2010-03-26
AU2005322241B2 (en) 2010-02-18
MA29097B1 (fr) 2007-12-03
TNSN07240A1 (en) 2008-11-21
US20090214464A1 (en) 2009-08-27

Similar Documents

Publication Publication Date Title
NO20073765L (no) Forbindelser for behandling av flaviviridae
NO20061479L (no) Anvendelse av modifiserte cyklosporiner for behandling av HCV-forstyrrelser
ITMI20041550A1 (it) Uso di batteri probiotici per la preparazione di composizioni topiche per la protezione dell'epidermide
BRPI1007379B8 (pt) composições farmacêuticas para o tratamento ou prevenção de infecções orais por e. coli
BRPI0413234A (pt) derivados de imidazola bicìclica contra flaviviridae
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
MY145721A (en) Non-irritating compositions containing zinc salts
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
EA200870019A1 (ru) Лактамовые соединения и способы их применения
DK1419154T3 (da) Rapamycin-29-enoler
EA200802166A1 (ru) Стабильная фармацевтическая композиция с защитным действием от раздражения (варианты), способ ее получения и способ лечения кальций-миметиком с ее помощью
ATE489957T1 (de) Mittel zur behandlung von entzündlichen erkrankungen
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
MX2007005590A (es) Compuestos del inhibidor glicogeno fosforilasa y sus composiciones farmaceuticas.
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
NO20070726L (no) Koblede pyrimidoner anvendbare i behandling eller forebygging av kreft
BRPI0509140A (pt) processos para o tratamento de infecção por hiv
MX2007007598A (es) Macrolidos.
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
DE602007011975D1 (de) Thiadiazolderivate zur behandlung neurodegenerativer krankheiten
DE602004025689D1 (de) Antivirale mittel zur behandlung, kontrolle und prävention von infektionen durch coronaviren
EA201400423A1 (ru) Фармацевтические препараты и их применение при лечении половой дисфункции у женщин
WO2009089147A3 (en) Methods and compositions for the treatment of cancers and pathogenic infections
UA107177C2 (uk) Імуногенна композиція цвс2 та спосіб приготування такої композиції

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.